BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 34333179)

  • 1. Risk Factors for and the Prognostic Impact of Pericardial Effusion after Allogeneic Hematopoietic Stem Cell Transplantation.
    Kubo H; Imataki O; Fukumoto T; Oku M; Ishida T; Kubo YH; Kida JI; Uemura M; Fujita H; Ohno H; Ide M; Ohnishi H; Kadowaki N
    Transplant Cell Ther; 2021 Nov; 27(11):949.e1-949.e8. PubMed ID: 34333179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of the simple L-index and absolute lymphocyte count early after allogeneic hematopoietic stem cell transplantation.
    Kubo H; Imataki O; Fukumoto T; Ishida T; Kubo YH; Kida JI; Uemura M; Fujita H; Kadowaki N
    Cytotherapy; 2023 Apr; 25(4):415-422. PubMed ID: 36599773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical characteristics and risk factors of pericardial effusion after hematopoietic stem cell transplantation in children with thalassemia major].
    Yang CL; Wang XD; Zhou XH; Wang CJ; Zhang XL; Li Y; Yu Y; Liu SX
    Zhonghua Er Ke Za Zhi; 2022 Apr; 60(4):323-328. PubMed ID: 35385938
    [No Abstract]   [Full Text] [Related]  

  • 6. Retrospective study of risk factors for pericardial effusion after haematopoietic stem cell transplantation in children.
    Tong K; Meng Y; Zhang L; Lei X; Guan X; Xiao L; Yu J; Dou Y
    Hematology; 2023 Dec; 28(1):2245259. PubMed ID: 37551721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
    Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
    Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
    Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
    Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
    Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
    Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical analysis of 14 patients aged ≤ 50 years with high-risk multiple myeloma treated with allogeneic hematopoietic stem cell transplantation].
    Pan P; Wang JL; Zhai WH; Ma QL; Yang DL; Feng SZ; Han MZ; Pang AM; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):28-34. PubMed ID: 38527835
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
    Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Allogeneic hematopoietic stem cell transplantation for treatment of refractory and relapsed acute myeloid leukemia: outcomes and prognostic factors].
    Su XH; Yao JF; Zhang GX; He Y; Wei JL; Ma QL; Yang DL; Huang Y; Zhai WH; Liang C; Li G; Chen X; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1024-1030. PubMed ID: 29365394
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk factors for pericardial effusion in adult patients receiving allogeneic haematopoietic stem cell transplantation.
    Liu YC; Chien SH; Fan NW; Hu MH; Gau JP; Liu CJ; Yu YB; Liu CY; Hsiao LT; Liu JH; Chiou TJ; Tzeng CH
    Br J Haematol; 2015 Jun; 169(5):737-45. PubMed ID: 25818840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretransplantation EASIX Score Predicts Nonrelapse and Overall Mortality of Adult Patients Undergoing Single-Unit Unrelated Cord Blood Transplantation.
    Fujita S; Monna-Oiwa M; Kato S; Isobe M; Takahashi S; Nannya Y; Konuma T
    Transplant Cell Ther; 2023 Sep; 29(9):580.e1-580.e8. PubMed ID: 37402420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation.
    Kaito S; Wada A; Adachi H; Konuma R; Kishida Y; Nagata A; Konishi T; Yamada Y; Kumagai T; Yoshifuji K; Mukae J; Akiyama M; Inamoto K; Toya T; Igarashi A; Najima Y; Muto H; Kobayashi T; Kakihana K; Ohashi K; Sakamaki H; Doki N
    Ann Hematol; 2020 Jul; 99(7):1655-1665. PubMed ID: 32524200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts.
    Jacob RP; Flynn J; Devlin SM; Maloy M; Giralt SA; Maslak P; O'Reilly RJ; Tonon JA; Perales MA; Avecilla ST; Cho C
    Transplant Cell Ther; 2021 Aug; 27(8):697.e1-697.e5. PubMed ID: 33991721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pericardial Effusion as a Purported Manifestation of Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation.
    Matin A; Smith BH; Mangaonkar A; Duffy DJ; Wolf R; Alkhateeb H; Shah MV; Hogan WJ; Litzow MR
    Transplant Cell Ther; 2023 May; 29(5):324.e1-324.e6. PubMed ID: 36682472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.
    Afrough A; Alsfeld LC; Milton DR; Delgado R; Popat UR; Nieto Y; Kebriaei P; Oran B; Saini N; Srour S; Hosing C; Cheema FH; Ahmed S; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Weber DM; Orlowski RZ; Pinnix CC; Dabaja BS; Thomas SK; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
    Transplant Cell Ther; 2023 Apr; 29(4):264.e1-264.e9. PubMed ID: 35605883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study.
    Yu J; Du Y; Ahmad S; Patel RD; Varela JC; Chang CC; Mori S
    Transplant Cell Ther; 2021 Aug; 27(8):663.e1-663.e6. PubMed ID: 33951497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.